Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.

Oncotarget · 2015 · PMC4496240 · PMID 25797254

Europe PMC DOI

hedged sentence

0.0701

closest p · 1.4× alpha

0.0701

boldest claim

The sentences

did not reach statistical significanceP=0.0701so close (0.05 < p ≤ 0.1)

Also, the RCC patients with positive methylation had a higher stage as compared to those with negative methylation, though the difference did not reach statistical significance (P=0.0701).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.